A Behavioral Adherence Intervention Improves Rates of Viral Suppression Among Adherence-Challenged People Living with HIV in South India
The success of antiretroviral therapy (ART) has led to both extended life expectancy and improved quality of life among people living with HIV (PLWH). To maximize the efficacy of first line ART regimens in low- and middle-income countries (LMIC), we need culturally-relevant interventions that empower participants to reduce barriers to long-term uninterrupted adherence. The Chetana adherence intervention trial was designed in collaboration with local community groups as a comprehensive wellness program for adherence-challenged PLWH and included peer-led adherence support, yoga, nutrition, information about local resources, and individual counseling using motivational interviewing techniques. Intervention arm participants were almost twice as likely to be virally suppressed at their 12-month follow-up visit (AOR = 1.98; 95% CI [1.2, 3.23]) as were participants in the active control arm. They were also about twice as likely as control arm participants to self-report ≥ 95% adherence (AOR = 1.86, 95% CI [1.09, 3.15]), and as having eliminated individual adherence barriers (AOR = 2.33, 95% CI [1.51, 3.62]) and clinic attendance barriers (AOR = 2.01, 95% CI [1.20, 3.38]) These low-cost strategies can be implemented by local NGOs, making it both scalable and sustainable in this and similar settings.
KeywordsHIV ART adherence trial Viral suppression India PLWH LMIC Cultural relevance
We gratefully acknowledge the staff at the Karnataka ART Centres for referring the study participants as well as the Chetana study staff for their hard work and dedication to the study participants. Finally, we are grateful to the many study participants who so generously shared their time and thoughts with us.
ME and SC conceived of and designed the study. The first draft of the manuscript was written by ME and EH. All authors commented on previous versions of the manuscript, read and approved the final manuscript.
This study was funded by the National Institutes of Health (R01MH095659).
Compliance with Ethical Standards
Conflict of interest
The authors declare they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standard of the Ethics Committees of the University of California, San Francisco and St. John’s Research Institute and with the 1964 Helsinki declaration and its later amendments or comparable ethical standard.
Informed consent was obtained from all individual participants included in the study.
- 3.UNAIDS. UNAIDS Data 2018. Geneva, Switzerland; 2018.Google Scholar
- 15.Byakika-Tusiime J, Crane J, Oyugi JH, Ragland K, Kawuma A, Musoke P, et al. Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS Behav. 2009;13(Suppl 1):82–91.PubMedCrossRefPubMedCentralGoogle Scholar
- 18.Orrell C, Cohen K, Mauff K, Maartens G, Wood R, DR. B. Randomised controlled trial of text-message dosing reminders in patients starting ART. 22nd Conference on Retroviruses and Opportunistic Infections (CROI), Abstract 559. Seattle, WA, February 23–26, 2015.Google Scholar
- 22.Safren SA, Biello KB, Smeaton L, Mimiaga MJ, Walawander A, Lama JR, et al. Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS ONE ONE. 2014;9(8):e104178.CrossRefGoogle Scholar
- 24.Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS Care. 2012;25:400–14.Google Scholar
- 25.Ekstrand ML, Shet A, Chandy S, Singh G, Shamsundar R, Madhavan V, et al. Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India. Int Health. 2011;3(1):27–34.PubMedPubMedCentralCrossRefGoogle Scholar
- 28.Venkatesh KK, Srikrishnan AK, Mayer KH, Kumarasamy N, Raminani S, Thamburaj E, et al. Predictors of nonadherence to highly active antiretroviral therapy among HIV-infected South Indians in clinical care: implications for developing adherence interventions in resource-limited settings. AIDS Patient Care STDs. 2010;24:795–803.PubMedPubMedCentralCrossRefGoogle Scholar
- 32.Liu H, Miller LG, Hays RD, Golin CE, Wu T, Wenger NS, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006;41(3):315–22.PubMedCrossRefPubMedCentralGoogle Scholar
- 38.Steward WT, Chandy S, Singh G, Panicker ST, Osmand TA, Heylen E, et al. Depression is not an inevitable outcome of disclosure avoidance: HIV stigma and mental health in a cohort of HIV-infected individuals from Southern India. Psychol Health Med. 2011;16(1):74–85.PubMedPubMedCentralCrossRefGoogle Scholar
- 40.de Bruin M, Oberjé EJ, Viechtbauer W, Nobel H-E, Hiligsmann M, van Nieuwkoop C, et al. Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial. Lancet Infect Dis. 2017;17(6):595–604.PubMedCrossRefGoogle Scholar
- 43.Abas M, Nyamayaro P, Bere T, Saruchera E, Mothobi N, Simms V, et al. Feasibility and acceptability of a task-shifted intervention to enhance adherence to HIV medication and improve depression in people living with HIV in Zimbabwe, a low income country in Sub-Saharan Africa. AIDS Behav. 2018;22(1):86–101.PubMedCrossRefGoogle Scholar
- 44.Bere T, Nyamayaro P, Magidson JF, Chibanda D, Chingono A, Munjoma R, et al. Cultural adaptation of a cognitive-behavioural intervention to improve adherence to antiretroviral therapy among people living with HIV/AIDS in Zimbabwe: Nzira Itsva. J Health Psychol. 2017;22(10):1265–76.PubMedCrossRefGoogle Scholar
- 45.National Aids Control Organization (NACO) MoHaFW, Governemnt of India; National Strategic Plan for HIV/AIDS and STI 2017–2014. New Delhi, India: NACO; 2017.Google Scholar